

ERBB2 & CD3E Research Grade Runimotamab

Catalog No. DHC09612A Quantity: $100 \mu g$

DHC09612B 1.0 mg

Alternate Names: Bispecific, BTRC-4017A, RG-6194, CAS: 2361325-98-4

Description: Research Grade Runimotamab is a humanized T-cell dependent bispecific (TDB)

monoclonal antibody with potential immunostimulatory and antineoplastic activities. Upon administration, runimotamab possesses two antigen recognition sites, one for HER2, a tyrosine kinase receptor overexpressed by many cancer cell types, and one for the CD3 complex, a group of T-cell surface glycoproteins that interact with the T-cell receptor (TCR). Upon administration of runimotamab, this bispecific monoclonal antibody

simultaneously binds to both CD3-expressing T cells and HER2-expressing cancer cells, thereby crosslinking HER2-expressing tumor cells and cytotoxic T lymphocytes (CTLs). This may result in potent CTL-mediated lysis of HER2-expressing tumor cells. HER2

plays a key role in tumor cell proliferation and tumor vascularization.

UniProt ID (target): P04626 & P07766

Target: Human HER2 (CD340) and CD3e

Concentration: 1.0 mg/ml, lot specific

Source: XtenCHO

Isotype: Human IgG1 kappa

Formulation: Sterile-filtered 0.01 M PBS, pH 7.4

Purity: > 95% by SDS-PAGE

Endotoxin Level: $\leq 0.01 \text{ EU/}\mu\text{g}$ by LAL analysis

Purification: Protein A/G affinity chromatography

INN: Runimotamab


Applications: Functional studies

Bioactivity: $EC_{50} = 46.86 \text{ ng/ml by indirect ELISA}$

Storage & Stability: Store at 2-8°C for up to 1 week, or in working aliquots at -20°C to -80°C for up to 1 year.

Avoid freeze/thaw cycles.

NOT FOR HUMAN USE. FOR RESEARCH ONLY, NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.



Toll Free: 888-769-1246 E-mail: info@cellsciences.com
Phone: 978-572-1070 Website: www.cellsciences.com
Fax: 978-992-0298